B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Home/Manufacturers
Supply base

The three manufacturers behind our portfolio

China licenses around thirty companies to fractionate plasma. We carry three, and the reason is not that the others are worse — it is that an export mandate can only be built on manufacturers who already have a regulatory trail.

Side by side

Manufacturer Centres Portfolio Foreign GMP record Supplied
China Resources Boya300294 · Fuzhou 21 10 plasma · 31 presentations Türkiye GMP cert · PH waiver 7
Beijing Bohui Innovation300318 · Beijing 23 8 plasma · 27 presentations + 1 vaccine None stated 9
Guangzhou BaiyunshanGPHL · Guangzhou — 1 vaccine Registration not initiated 1

Collection centres are the single best proxy for plasma capacity in China: manufacturers cannot buy plasma on the open market, so the number of licensed collection sites is the real ceiling on output. "Foreign GMP record" means an inspection or certificate from a regulator outside China — an NMPA approval number alone does not count.

Why only three

An export mandate is not a directory. Taking on a manufacturer means holding their dossier, releasing their documents, answering for their lead times and standing behind their batches in a market we can be sued in. Doing that for thirty companies would mean doing it badly for all of them.

Three manufacturers, seventeen products. Every product page names the manufacturer, the approval number and the document set. Nothing is listed that we cannot release paperwork for.

The three profiles

What a profile page is for

Each manufacturer page exists so that a buyer can answer three questions without an email: who the legal entity is, what they actually manufacture, and how to check the licences independently. The approval numbers, the batch-release rule and the public filings are all reachable — a supplier who would rather you did not look is telling you something.

Our compliance statement covers what we hold and what we do not, and Insights has the longer explanations of how Chinese drug approval and batch release work.